Loading
Drug candidates are tested for shrinking tumours, almost never for stopping spread. A standard spread test would find anti-metastatic drugs we are throwing away.
Barcoded in vivo CRISPR and lineage-tracing screens can quantify seeding, survival in circulation and outgrowth as separate phenotypes. Very few programmes run them, so anti-metastatic activity is invisible during discovery. Funders could require a standard metastasis panel (spontaneous metastasis from orthotopic implantation plus a barcoded seeding assay) from any grant or programme claiming anti-metastatic intent.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, DepMap (Cancer Dependency Map), Patient-derived xenografts, Patient-derived organoids.
Shares Patient-derived xenografts, CRISPR functional genomics, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Are 90% of deaths from cancer caused by metastases?, Patient-derived xenografts, Metastasis is understood least and studied last, Patient-derived organoids.
Shares Patient-derived xenografts, Metastasis is understood least and studied last, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares DepMap (Cancer Dependency Map), CRISPR functional genomics, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, DepMap (Cancer Dependency Map), Patient-derived organoids, Lab models that fail to predict what happens in patients.